For progression-free survival rates, the univariate analysis indicated that tumor size, lymph node metastasis, FIGO staging, and Hec1 expression were significant risk factors (Table 4). This evidence concerns the gene NDC80 and metastatic malignant neoplasm in the lymph nodes.